

AIMP1

EMAP-II, Human Recombinant

Catalog No.	CRE200A CRE200B CRE200C	Quantity:	5 µg 20 µg 1.0 mg
Description:	Recombinant Human EMAP-II is a single non-glycosylated polypeptide chain containing 166 amino acids.		
GeneID:	9255		
Source:	<i>E. coli</i>		
Molecular Weight:	18.3 kDa		
Formulation:	Lyophilized from a sterile filtered solution in 20 mM PB, pH 7.4 + 130 mM NaCl.		
Purity:	>98% by SDS-PAGE and HPLC analyses.		
Endotoxin Level:	< 0.1 ng/µg of Recombinant Human EMAP-II (1 EU/µg)		
Biological Activity:	Determined by the apoptotic effect on MCF-7 cells using a concentration of 20-40 ng/ml.		
Amino Acid Sequence:	SKPIDVSRLD LRIGCIITAR KHPDADSLYV EEVDVGEIAP RTVVSGLVNH VPLEQMQRNM VILLCNLKPA KMRGVLSQAM VMCASSPEKI EILAPPNGSV PGDRITFDAF PGEPDKELNP KKKIWEQIQP DLHTNDECVA TYKGVPFVEVK GKGVCRAQTM SNSGIK		
Reconstitution:	Centrifuge vial prior to opening. Add sterile distilled water or aqueous buffer to a concentration of 0.1-1.0 mg/mL. Further dilutions should be made in appropriate buffered solutions.		
Storage & Stability:	Stable at 2-8°C, but best kept desiccated -20°C. Upon reconstitution, stable for up to 1 week at 2-8°C. For longer term, store in working aliquots below -20°C. Avoid repeated freeze/thaw cycles.		
Background:	EMAP-II is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.